Sign in

BLRX on Nasdaq

Bioline Rx Ltd.

Logo: biolinerx.com5

Israeli drug development company

BioLineRx Ltd. (Hebrew: ביוליין אר אקס), or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.3 Its shares trade on Nasdaq under the symbol BLRX.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

2003Founded1

Compare with ALX ONCOLOGY HOLDINGS INC, Neuphoria Therapeutics Inc. or Longeveron Inc., or pick any stock.

  • TickerBLRX on Nasdaq1
  • Industrybiotechnology1
  • HeadquartersJerusalem1
  • Founded inIsrael1
  • Websitewww.biolinerx.com
  • Legal formlimited company1
  • Listed onNasdaq (BLRX), Tel Aviv Stock Exchange (BLRX)1
  • Incorporated inIsrael6
  • Business address2 Hamaayan Street, Modi-In Technology Park, Modi-In, Israel6
  • Filer categoryNon-accelerated filer6
  • LEI529900AKIOSC15Y63R184
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressModi'in Technology Park, 2 HaMa'ayan Street, 7177871 Modi'in, Israel4
  • Registered withIsraeli Corporations Authority (Department of Justice), 5133987504

See how the biggest companies compare on our leaderboards

Hotzvimview
Photo: Gilabrand, CC BY-SA 3.0, via Wikimedia Commons8

BioLineRx Ltd. (Hebrew: ביוליין אר אקס), or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

80.5%Gross margin9
-871.8%Operating margin9
-171.7%Net margin9
-95.9%Revenue growth, 20259
-8.7%Return on equity9
-$8.1MFree cash flow9

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue2¢$230.0K
  • Research and development64¢$8.1M
  • Selling, general and admin25¢$3.1M
  • Interest10¢$1.3M

Out of $1.2M in revenue.9 The company lost money this year.

Financial statements

Revenue10119$1.2M in 2025
0$10.0M$20.0M$30.0M2021: $0$020212022: $0$020222023: $4.8M$4.8M20232024: $28.9M$28.9M2024+503%2025: $1.2M$1.2M2025−96%
Gross profit10119$950.0K in 2025
0$5.0M$10.0M$15.0M$20.0M2021: $0$020212022: $0$020222023: $1.1M$1.1M20232024: $19.7M$19.7M2024+1676%2025: $950.0K$950.0K2025−95%
Operating income121310119-$10.3M in 2025−63% since 2019
-$60.0M-$40.0M-$20.0M02019: -$28.1M-$28.1M20192020: -$22.9M-$22.9M2020−18%2021: -$24.8M-$24.8M2021+8%2022: -$29.2M-$29.2M2022+18%2023: -$49.7M-$49.7M2023+70%2024: -$20.4M-$20.4M2024−59%2025: -$10.3M-$10.3M2025−50%
Net income121310119-$2.0M in 2025−92% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$25.4M-$25.4M20192020: -$30.0M-$30.0M2020+18%2021: -$27.1M-$27.1M2021−10%2022: -$25.0M-$25.0M2022−8%2023: -$60.6M-$60.6M2023+143%2024: -$9.2M-$9.2M2024−85%2025: -$2.0M-$2.0M2025−78%
Fiscal year2019202020212022202320242025
Revenue$010$011$4.8M9$28.9M9$1.2M9
Cost of revenue$010$011$3.7M9$9.3M9$230.0K9
Gross profit$010$011$1.1M9$19.7M9$950.0K9
Research and development$19.5M10$17.6M11$12.5M9$9.1M9$8.1M9
Selling, general and admin$4.3M10$5.1M11$6.3M9$6.3M9$3.1M9
Operating income-$28.1M12-$22.9M13-$24.8M10-$29.2M11-$49.7M9-$20.4M9-$10.3M9
Interest$984.0K10$1.8M11$2.1M9$9.1M9$1.3M9
Income tax$010$011$09$09$09
Net income-$25.4M12-$30.0M13-$27.1M10-$25.0M11-$60.6M9-$9.2M9-$2.0M9
Earnings per share-$0.1213-$0.0410-$0.0311-$0.069-$0.019$0.009
Earnings per share (diluted)-$0.1213-$0.0410-$0.0311-$0.069-$0.019$0.009
Shares (weighted, basic)662.9M shares10774.0M shares11963.4M shares91.2B shares92.5B shares9
Shares (weighted, diluted)963.4M shares91.2B shares92.5B shares9

Compare Bioline Rx Ltd. with another company

Corporate structure

Bioline Rx Ltd. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Bioline Rx Ltd.

  • Bioline Rx Ltd. Modi'in, Israel

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Bioline Rx Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$160.0K9 Dec 31, 2025$386.0K9 Dec 31, 2024−58.5%
Operating-lease assets (leased space)$696.0K9 Dec 31, 2025$967.0K9 Dec 31, 2024−28.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$3.2M9 Dec 31, 2025$10.4M9 Dec 31, 2024−68.9%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$16.4M9 Dec 31, 2025$10.4M9 Dec 31, 2024+56.6%

Inventory

ItemLatestA year beforeChange
Inventory, total$2.1M9 Dec 31, 2025$3.1M9 Dec 31, 2024−31.7%
Raw materials$011 Dec 31, 2024$903.0K11 Dec 31, 2023−100.0%

The story

The firm was established in 2003 as a joint venture of Teva, Hadasit Bio-Holdings, the Jerusalem Development Authority, Yehuda Zisapel, and other investors. It executed an initial public offering on the Tel Aviv Stock Exchange in February 2007, raising 211 million NIS ($50 million) – the TASE's largest biotech IPO until that time. In July 2011 BioLine's ADRs began trading on the NASDAQ Capital Market. In January 2012, the firm announced a deal with Genoscience, a French pharmaceutical company to jointly develop and market the BL-8020 compound, as a treatment for Hepatitis C. At the end of 2014, Novartis acquired a 12.8% stake in the company as a strategic move to gain access to Israeli-sourced drug candidates.

Management

Morris Laster, (M.D.) an alumnus of. Downstate Medical Center, was CEO of BioLineRx until 2009. He was replaced by Kinneret Savitsky, alumnus of Tel Aviv University early in 2010. Savitsky was replaced as CEO by BioLine COO Philip Serlin on October 10, 2016.

From Wikipedia’s article on BioLineRx, shared under CC BY-SA 4.0.7

Leadership

Who has led Bioline Rx Ltd., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Philip A. Serlin2026–now

Chief financial officer

  1. Mali Zeevi2026–now
20052010201520202025
Board members and other officers (7)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Chief Development OfficerElla A. Sorani named Sep 9, 202625
  • DirectorBJ A. Bormann named Sep 9, 202625
  • DirectorSandra A. Panem named Sep 9, 202625

Products and brands

BioLineRx is a drug development company When promising compounds are discovered, the firm leads them through preclinical trials and engages other companies to further develop them into commercializable drugs. The company entered into its first major commercialization agreement in 2009 when it partnered with Ikaria Holdings Inc. to develop its BL-1040 compound. In 2010, BioLine entered into a commercialization agreement with Cypress Bioscience Inc. for development of its BL-1020 compound. The agreement with Cypress was canceled in 2011 when the company was taken over by Ramius LLC.

Pipeline

Below is a partial list of drug compounds in various stages of development by BioLineRx. Unless indicated otherwise, they have not obtained regulatory approval in relation to the diseases cited.

BL-1010 – orally available neuropathic pain

BL-1020 – orally available GABA-enhanced antipsychotic for treatment of schizophrenia

Read the full text

BL-1021 – orally available small molecule for treatment of neuropathic pain

BL-1040 – liquid polymer injected into patients with acute myocardial infarction, invented by Smadar Cohen of Ben-Gurion University

BL-1230 - a selective cannabinoid receptor type 2 (CB2R) agonist for Dry Eye Syndrome (DES)

BL-5010 – cream treatment for seborrheic keratosis skin lesions

BL-7040 – orally available anti-inflammatory drug invented by Hermona Soreq of the Hebrew University of Jerusalem

BL-8020 – orally administered treatment for Hepatitis C, developed by Philippe Halfon, co-founder and President of Genoscience.

BL-8030 – second-generation NS3 protease inhibitor for oral treatment of Hepatitis C, invented by Philippe Halfon

From Wikipedia’s article on BioLineRx, shared under CC BY-SA 4.0.7

Timeline

  1. Mar 27, 2026New chief executive Philip A. Serlin becomes CEO16
  2. 2003Founded Founded in Israel1

Calendar

Coming up

  1. Nov 23, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.22) a share, on Nov 24, 2025.26

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

131 filings to the SEC since October 2021: 8 annual reports, 10 insider forms, 4 large holders, 1 private raises, 108 other. The latest 20:

  1. Oct 2, 2026EFFECT EDGAR
  2. Oct 2, 2026424B3 EDGAR
  3. Sep 25, 2026F-1 EDGAR
  4. Sep 24, 20266-K EDGAR
  5. Sep 10, 20266-K EDGAR
  6. Sep 9, 2026D EDGAR
  7. Aug 31, 2026424B5 EDGAR
  8. Aug 31, 20266-K EDGAR
  9. Aug 31, 20266-K EDGAR
  10. Aug 28, 20266-K EDGAR
  11. Aug 18, 20266-K EDGAR
  12. Jul 8, 20266-K EDGAR
  13. May 27, 20266-K EDGAR
  14. May 22, 20266-K EDGAR
  15. May 19, 20266-K EDGAR
  16. Apr 28, 20266-K EDGAR
  17. Apr 10, 20263 EDGAR
  18. Mar 31, 20263 EDGAR
  19. Mar 31, 20263 EDGAR
  20. Mar 31, 20263 EDGAR

The 131 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$3.8M 2026–2026
Money received by yearMoney received by year, 2026–2026: $3.8M in all. Private raises (Form D) $3.8M.$0$1M$2M$3M$4M2026 · Private raises (Form D): $3.8M2026
Figures by year
YearPrivate raises (Form D)Total
2026$3.8M$3.8M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Aug 27, 2026Raised $3.8 million in a private offering of securities25 Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Susquehanna International Group, Llp30,911$95.8K0.0%New
Renaissance Technologies LLC15,412$48.1K0.0%New
Citadel Advisors LLC14,796$45.9K0.0%New
Rhumbline Advisers2,478$7.7K0.0%+125
Wells Fargo & Company/mn2,000$6.2K0.0%+250
Bnp Paribas Financial Markets500$1.6K0.0%−1,300
Banque Cantonale Vaudoise1$1.0K0.0%No change
Nemes Rush Group LLC250$7800.0%No change
UBS Group AG101$3150.0%−428
NewEdge Advisors, LLC82$2560.0%−25
Osaic Holdings, Inc.26$810.0%No change
SBI Securities Co., Ltd.10$310.0%New
Danske Bank A/s2$60.0%No change
Citigroup Inc1$30.0%−1,727

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Bioline Rx Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBioLineRx Ltd.2
  • CIK0001498403
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company30
  • Incorporated inIsrael30
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address2 Hamaayan Street, Modi-In Technology Park, Modi-In, ISRAEL, Israel2
  • Phone972-8-642-91002
  • Shares outstanding2,610,814,390 shares as of Mar 8, 202630
  • AuditorKesselman & Kesselman, Tel Aviv, Israel PCAOB ID 1309; no auditor attestation of internal control over financial reporting30
  • On EDGAR sinceSep 24, 20102
  • Filings616 in all: 6-K (398), 424B5 (31), SC 13G/A (23), SC 13G (19), CT ORDER (18), EFFECT (16), 20-F (15), 20-F/A (10)2
    All 32 form types

    3 (10), 424B3 (8), S-8 (8), SC 13D/A (8), F-3 (7), CORRESP (5), F-1 (5), F-3/A (5), UPLOAD (5), POS AM (4), D (3), SC 13D (3), F-1/A (2), FWP (2), SCHEDULE 13G (2), 20FR12B (1), 20FR12B/A (1), 424B2 (1), 6-K/A (1), AW (1), CERTNAS (1), F-6 (1), RW (1), S-8 POS (1)

  • Latest filingsAnnual report (20-F) Mar 23, 2026

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
    Company websiteBioline Rx Ltd. logo
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30